<?xml version='1.0' encoding='utf-8'?>
<document id="27510521"><sentence text="Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction."><entity charOffset="0-12" id="DDI-PubMed.27510521.s1.e0" text="Voriconazole" /><entity charOffset="30-42" id="DDI-PubMed.27510521.s1.e1" text="posaconazole" /><entity charOffset="83-96" id="DDI-PubMed.27510521.s1.e2" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.27510521.s1.e0" e2="DDI-PubMed.27510521.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27510521.s1.e0" e2="DDI-PubMed.27510521.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27510521.s1.e0" e2="DDI-PubMed.27510521.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27510521.s1.e1" e2="DDI-PubMed.27510521.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27510521.s1.e1" e2="DDI-PubMed.27510521.s1.e2" /></sentence><sentence text="This study aimed to determine possible effects of voriconazole and posaconazole on the pharmacokinetics and pharmacological effects of sublingual buprenorphine"><entity charOffset="50-62" id="DDI-PubMed.27510521.s2.e0" text="voriconazole" /><entity charOffset="67-79" id="DDI-PubMed.27510521.s2.e1" text="posaconazole" /><entity charOffset="146-159" id="DDI-PubMed.27510521.s2.e2" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.27510521.s2.e0" e2="DDI-PubMed.27510521.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27510521.s2.e0" e2="DDI-PubMed.27510521.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27510521.s2.e0" e2="DDI-PubMed.27510521.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27510521.s2.e1" e2="DDI-PubMed.27510521.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27510521.s2.e1" e2="DDI-PubMed.27510521.s2.e2" /></sentence><sentence text="" /><sentence text="We used a randomized, placebo-controlled crossover study design with 12 healthy male volunteers" /><sentence text=" Subjects were given a dose of 0" /><sentence text="4 mg (0" /><sentence text="6 mg during placebo phase) sublingual buprenorphine after a 5-day oral pretreatment with either (i) placebo, (ii) voriconazole 400 mg twice daily on the first day and 200 mg twice daily thereafter or (iii) posaconazole 400 mg twice daily"><entity charOffset="38-51" id="DDI-PubMed.27510521.s7.e0" text="buprenorphine" /><entity charOffset="114-126" id="DDI-PubMed.27510521.s7.e1" text="voriconazole" /><entity charOffset="206-218" id="DDI-PubMed.27510521.s7.e2" text="posaconazole" /><pair ddi="false" e1="DDI-PubMed.27510521.s7.e0" e2="DDI-PubMed.27510521.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27510521.s7.e0" e2="DDI-PubMed.27510521.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27510521.s7.e0" e2="DDI-PubMed.27510521.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27510521.s7.e1" e2="DDI-PubMed.27510521.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27510521.s7.e1" e2="DDI-PubMed.27510521.s7.e2" /></sentence><sentence text=" Plasma and urine concentrations of buprenorphine and its primary active metabolite norbuprenorphine were monitored over 18 h and pharmacological effects were measured"><entity charOffset="36-49" id="DDI-PubMed.27510521.s8.e0" text="buprenorphine" /><entity charOffset="84-100" id="DDI-PubMed.27510521.s8.e1" text="norbuprenorphine" /><pair ddi="false" e1="DDI-PubMed.27510521.s8.e0" e2="DDI-PubMed.27510521.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27510521.s8.e0" e2="DDI-PubMed.27510521.s8.e1" /></sentence><sentence text="" /><sentence text="Compared to placebo, voriconazole increased the mean area under the plasma concentration-time curve (AUC0-∞) of buprenorphine 1"><entity charOffset="21-33" id="DDI-PubMed.27510521.s10.e0" text="voriconazole" /><entity charOffset="112-125" id="DDI-PubMed.27510521.s10.e1" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.27510521.s10.e0" e2="DDI-PubMed.27510521.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27510521.s10.e0" e2="DDI-PubMed.27510521.s10.e1" /></sentence><sentence text="80-fold (90 % confidence interval 1" /><sentence text="45-2" /><sentence text="24; P &lt; 0" /><sentence text="001), its peak concentration (Cmax) 1" /><sentence text="37-fold (P &lt; 0" /><sentence text="013) and half-life (t ½ ) 1" /><sentence text="37-fold (P &lt; 0" /><sentence text="001)" /><sentence text=" Posaconazole increased the AUC00-∞ of buprenorphine 1"><entity charOffset="1-13" id="DDI-PubMed.27510521.s19.e0" text="Posaconazole" /><entity charOffset="39-52" id="DDI-PubMed.27510521.s19.e1" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.27510521.s19.e0" e2="DDI-PubMed.27510521.s19.e0" /><pair ddi="false" e1="DDI-PubMed.27510521.s19.e0" e2="DDI-PubMed.27510521.s19.e1" /></sentence><sentence text="25-fold (P &lt; 0" /><sentence text="001)" /><sentence text=" Most of the plasma norbuprenorphine concentrations were below the limit of quantification (0"><entity charOffset="20-36" id="DDI-PubMed.27510521.s22.e0" text="norbuprenorphine" /></sentence><sentence text="05 ng/ml)" /><sentence text=" Voriconazole, unlike posaconazole, increased the urinary excretion of norbuprenorphine 1"><entity charOffset="1-13" id="DDI-PubMed.27510521.s24.e0" text="Voriconazole" /><entity charOffset="22-34" id="DDI-PubMed.27510521.s24.e1" text="posaconazole" /><entity charOffset="71-87" id="DDI-PubMed.27510521.s24.e2" text="norbuprenorphine" /><pair ddi="false" e1="DDI-PubMed.27510521.s24.e0" e2="DDI-PubMed.27510521.s24.e0" /><pair ddi="false" e1="DDI-PubMed.27510521.s24.e0" e2="DDI-PubMed.27510521.s24.e1" /><pair ddi="false" e1="DDI-PubMed.27510521.s24.e0" e2="DDI-PubMed.27510521.s24.e2" /><pair ddi="false" e1="DDI-PubMed.27510521.s24.e1" e2="DDI-PubMed.27510521.s24.e1" /><pair ddi="false" e1="DDI-PubMed.27510521.s24.e1" e2="DDI-PubMed.27510521.s24.e2" /></sentence><sentence text="58-fold (90 % confidence interval 1" /><sentence text="18-2" /><sentence text="12; P &lt; 0" /><sentence text="001) but there was no quantifiable parent buprenorphine in urine"><entity charOffset="42-55" id="DDI-PubMed.27510521.s28.e0" text="buprenorphine" /></sentence><sentence text=" Plasma buprenorphine concentrations correlated with the pharmacological effects, but the effects did not differ significantly between the phases"><entity charOffset="8-21" id="DDI-PubMed.27510521.s29.e0" text="buprenorphine" /></sentence><sentence text="" /><sentence text="Voriconazole, and to a minor extent posaconazole, increase plasma exposure to sublingual buprenorphine, probably via inhibition of cytochrome P450 3 A and/or P-glycoprotein"><entity charOffset="0-12" id="DDI-PubMed.27510521.s31.e0" text="Voriconazole" /><entity charOffset="36-48" id="DDI-PubMed.27510521.s31.e1" text="posaconazole" /><entity charOffset="89-102" id="DDI-PubMed.27510521.s31.e2" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.27510521.s31.e0" e2="DDI-PubMed.27510521.s31.e0" /><pair ddi="false" e1="DDI-PubMed.27510521.s31.e0" e2="DDI-PubMed.27510521.s31.e1" /><pair ddi="false" e1="DDI-PubMed.27510521.s31.e0" e2="DDI-PubMed.27510521.s31.e2" /><pair ddi="false" e1="DDI-PubMed.27510521.s31.e1" e2="DDI-PubMed.27510521.s31.e1" /><pair ddi="false" e1="DDI-PubMed.27510521.s31.e1" e2="DDI-PubMed.27510521.s31.e2" /></sentence><sentence text=" Care should be exercised in the combined use of buprenorphine with triazole antimycotics, particularly with voriconazole, because their interaction can be of clinical importance"><entity charOffset="49-62" id="DDI-PubMed.27510521.s32.e0" text="buprenorphine" /><entity charOffset="68-76" id="DDI-PubMed.27510521.s32.e1" text="triazole" /><entity charOffset="109-121" id="DDI-PubMed.27510521.s32.e2" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.27510521.s32.e0" e2="DDI-PubMed.27510521.s32.e0" /><pair ddi="false" e1="DDI-PubMed.27510521.s32.e0" e2="DDI-PubMed.27510521.s32.e1" /><pair ddi="false" e1="DDI-PubMed.27510521.s32.e0" e2="DDI-PubMed.27510521.s32.e2" /><pair ddi="false" e1="DDI-PubMed.27510521.s32.e1" e2="DDI-PubMed.27510521.s32.e1" /><pair ddi="false" e1="DDI-PubMed.27510521.s32.e1" e2="DDI-PubMed.27510521.s32.e2" /></sentence><sentence text="" /></document>